ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Inhibition of Cytochrome P450 3A4 by a Pyrimidineimidazole:  Evidence for Complex Heme Interactions

View Author Information
Pharmacokinetics, Dynamics and Metabolism (PDM), Department of Medicinal Chemistry, Pfizer Global Research and Development, 700 Chesterfield Parkway West T3A, Chesterfield, Missouri 63017, and Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455
Cite this: Chem. Res. Toxicol. 2006, 19, 12, 1650–1659
Publication Date (Web):November 24, 2006
Copyright © 2006 American Chemical Society

    Article Views





    Other access options
    Supporting Info (3)»


    Abstract Image

    PH-302 inhibits the inducible form of nitric oxide synthase (iNOS) by coordinating with the heme of the monomeric form and preventing formation of the active dimer. Inherent with the mechanism of pharmacology for this compound was the inhibition of cytochrome P450 3A4 (P450 3A4), observed from early ADME screening. Further investigation showed that PH-302 inhibited P450 3A4 competitively with a Ki of ∼2.0 μM against both midazolam and testosterone hydroxylation in human liver microsomes. As expected, spectral binding analysis demonstrated that inhibition was a result of type II coordination to the P450 heme with the imidazole moiety of PH-302, although only 72% of the maximal absorbance difference was achievable with PH-302 compared to that of the smaller ligand imidazole. Time-dependent inhibition of P450 3A4 by PH-302 was also observed because of metabolite-inhibitory (MI) complex formation via metabolism of the methylenedioxyphenyl group. The profile for time-dependent inhibition in recombinant P450 3A4 was biphasic, and was kinetically characterized by a kinact of 0.08 min-1 and a Ki of 1.2 μM for the first phase (0−1.5 min) and a kinact of 0.06 min-1 and a Ki of 23.8 μM for the second phase (1.5−10 min). Spectral characterization of the PH-302 MI complex demonstrated that formation began to plateau within 3 min, consistent with the kinetic profile of inactivation by PH-302. Meanwhile, spectral evidence for the imidazole-derived type II difference spectrum of PH-302 was captured simultaneously with the formation of the MI complex. The presence of simultaneously operable type II coordination and rapidly saturable MI complex formation with heme by PH-302 indicates the presence of complex heme interactions with this unique molecule. Information from these mechanistic studies adds to our understanding of the nature of P450 3A4 inhibition by PH-302 and provides a potentially useful tool compound for future studies investigating binding interactions in this important drug-metabolizing enzyme.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.


     Corresponding author. Tel:  314-274-0261. Fax:  314-274-4426. E-mail:  [email protected].

     Pfizer Global Research and Development.

     University of Minnesota.


     Current address:  Amgen, Inc., Pharmacokinetics & Drug Metabolism, AW2-D / 2381, 1201 Amgen Court West, Seattle, WA 98119-3105.

    Supporting Information Available

    Jump To

    Initial P450 inhibition screening data showing potent inhibition of P450 3A4, IC50 data showing a shift in IC50 from 5.2 to 4.4 μM for inhibition of midazolam 1‘-hydroxylation following a 10 min preincubation of PH-302 in human liver microsomes, data demonstrating lack of significant depletion of PH-302 when incubated with P450 3A4 Supersomes under the same incubation conditions as those of the inactivation experiments, and verification of type II spectra with PH-302 with reduced Fe-II. This material is available free of charge via the Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 34 publications.

    1. Nikolette L. McCombs, Tadeo Moreno-Chicano, Leiah M. Carey, Stefan Franzen, Michael A. Hough, and Reza A. Ghiladi . Interaction of Azole-Based Environmental Pollutants with the Coelomic Hemoglobin from Amphitrite ornata: A Molecular Basis for Toxicity. Biochemistry 2017, 56 (17) , 2294-2303.
    2. Jiaming Chen, Ying Peng, and Jiang Zheng . Cytochrome P450 Mediated Bioactivation of Saracatinib. Chemical Research in Toxicology 2016, 29 (11) , 1835-1842.
    3. William M. Atkins and Hong Qian . Stochastic Ensembles, Conformationally Adaptive Teamwork, and Enzymatic Detoxification. Biochemistry 2011, 50 (19) , 3866-3872.
    4. J. Matthew Hutzler, Roger J. Melton, Jeanne M. Rumsey, David C. Thompson, Dan A. Rock, and Larry C. Wienkers . Assessment of the Metabolism and Intrinsic Reactivity of a Novel Catechol Metabolite. Chemical Research in Toxicology 2008, 21 (5) , 1125-1133.
    5. DAN A. ROCK, LARRY C. WIENKERS. Characterization of Cytochrome P450 Mechanism Based Inhibition. 2022, 465-526.
    6. Michael Mohutsky, Stephen D. Hall. Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions. 2021, 51-88.
    7. Chuong Pham, Swati Nagar, Ken Korzekwa. Numerical analysis of time-dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting. Xenobiotica 2020, 50 (11) , 1301-1310.
    8. Tiantian Cui, Qian Wang, Xiaoxiao Tian, Kehan Zhang, Ying Peng, Jiang Zheng. Piperine Is a Mechanism-Based Inactivator of CYP3A. Drug Metabolism and Disposition 2020, 48 (2) , 123-134.
    9. Yan Chen, Jing Yu, Xu Wang, Hui Li, Xu Mao, Ying Peng, Jiang Zheng. Characterization of glutathione conjugates derived from reactive metabolites of seven silymarin isomers. Xenobiotica 2019, 49 (11) , 1269-1278.
    10. Rebecca Elias, Raphael I. Benhamou, Qais Z. Jaber, Orly Dorot, Sivan Louzoun Zada, Keren Oved, Edward Pichinuk, Micha Fridman. Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles. European Journal of Medicinal Chemistry 2019, 179 , 779-790.
    11. Xu Mao, Zixia Hu, Qian Wang, Na Zhang, Shenzhi Zhou, Ying Peng, Jiang Zheng. Nitidine Chloride Is a Mechanism-Based Inactivator of CYP2D6. Drug Metabolism and Disposition 2018, 46 (8) , 1137-1145.
    12. Monika Židková, Igor Linhart, Marie Balíková, Michal Himl, Lubomír Váňa, Michal Vetýška, Tomáš Páleníček, Eva Lhotková, Martin Dušek. Study on the metabolism of 5,6-methylenedioxy-2-aminoindane (MDAI) in rats: identification of urinary metabolites. Xenobiotica 2017, 47 (6) , 505-514.
    13. José Pérez-del Palacio, Caridad Díaz, Noemí Vergara, Francesca Algieri, Alba Rodríguez-Nogales, Nuria de Pedro, M. Elena Rodríguez-Cabezas, Olga Genilloud, Julio Gálvez, Francisca Vicente. Exploring the Role of CYP3A4 Mediated Drug Metabolism in the Pharmacological Modulation of Nitric Oxide Production. Frontiers in Pharmacology 2017, 8
    14. Agnieszka Potęga, Barbara Fedejko-Kap, Zofia Mazerska. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes. Pharmacological Reports 2016, 68 (4) , 663-670.
    15. Xu Mao, Ying Peng, Jiang Zheng. In Vitro and In Vivo Characterization of Reactive Intermediates of Corynoline. Drug Metabolism and Disposition 2015, 43 (10) , 1491-1498.
    16. Maria Almira Correia, Paul. F. Hollenberg. Inhibition of Cytochrome P450 Enzymes. 2015, 177-259.
    17. Karine Auclair, Vanja Polic. Use of Chemical Auxiliaries to Control P450 Enzymes for Predictable Oxidations at Unactivated C-H Bonds of Substrates. 2015, 209-228.
    18. Vanja Polic, Karine Auclair. Controlling substrate specificity and product regio- and stereo-selectivities of P450 enzymes without mutagenesis. Bioorganic & Medicinal Chemistry 2014, 22 (20) , 5547-5554.
    19. Michael Mohutsky, Stephen D. Hall. Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions. 2014, 57-91.
    20. Emanuele Carosati. Modelling cytochromes P450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity. Drug Discovery Today: Technologies 2013, 10 (1) , e167-e175.
    21. Amin Kamel, Shawn Harriman. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). Drug Discovery Today: Technologies 2013, 10 (1) , e177-e189.
    22. Hemali T. Amunugama, Haoming Zhang, Paul F. Hollenberg. Mechanism-Based Inactivation of Cytochrome P450 2B6 by Methadone through Destruction of Prosthetic Heme. Drug Metabolism and Disposition 2012, 40 (9) , 1765-1770.
    23. Jeffrey P. Jones, Carolyn A. Joswig-Jones, Michelle Hebner, Yuzhuo Chu, Dennis R. Koop. The effects of nitrogen-heme-iron coordination on substrate affinities for cytochrome P450 2E1. Chemico-Biological Interactions 2011, 193 (1) , 50-56.
    24. Agnieszka Potega, Emilia Dabrowska, Magdalena Niemira, Agata Kot-Wasik, Sebastien Ronseaux, Colin J. Henderson, C. Roland Wolf, Zofia Mazerska. The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s. Drug Metabolism and Disposition 2011, 39 (8) , 1423-1432.
    25. Kip P. Conner, Caleb M. Woods, William M. Atkins. Interactions of cytochrome P450s with their ligands. Archives of Biochemistry and Biophysics 2011, 507 (1) , 56-65.
    26. J. Matthew Hutzler, Jack Cook, Joseph C. Fleishaker. Drug–Drug Interactions: Designing Development Programs and Appropriate Product Labeling. 2011, 21-56.
    27. Dan Rock, Larry C. Wienkers. Characterization of Cytochrome P 450 Mechanism‐Based Inhibition. 2010, 1-56.
    28. Karl J. Okolotowicz, Ranxin Shi, Xueying Zheng, Mary MacDonald, John C. Reed, John R. Cashman. Selective benzimidazole inhibitors of the antigen receptor-mediated NF-κB activation pathway. Bioorganic & Medicinal Chemistry 2010, 18 (5) , 1918-1924.
    29. Michael B. Fisher. Complexities of Working with UDP‐ Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition. 2009, 407-422.
    30. Dan Rock, Larry C. Wienkers. Characterization of Cytochrome P450 Mechanism‐Based Inhibition. 2009, 479-534.
    31. Bernard P. Murray. Chapter 26 Mechanism-Based Inhibition of CYP3A4 and Other Cytochromes P450. 2009, 535-553.
    32. Dan Rock, Jan Wahlstrom, Larry Wienkers. Cytochrome P450s: Drug–Drug Interactions. 2008, 195-246.
    33. Ren-Jie Song, Chen-Liang Deng, Ye-Xiang Xie, Jin-Heng Li. Solvent-free copper/iron co-catalyzed N-arylation reactions of nitrogen-containing heterocycles with trimethoxysilanes in air. Tetrahedron Letters 2007, 48 (44) , 7845-7848.
    34. Charles W. Locuson, J. Matthew Hutzler, Timothy S. Tracy. Visible Spectra of Type II Cytochrome P450-Drug Complexes: Evidence that “Incomplete” Heme Coordination Is Common. Drug Metabolism and Disposition 2007, 35 (4) , 614-622.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect